Artemisinin resistance is rising in East Africa—leaving anti-malarials at risk of failure

Resistance to the main drug in front-line malaria treatments is becoming more widespread across East Africa, according to new research by Imperial College London. The study, published in The Lancet Infectious Diseases, maps the rise in artemisinin resistance in the region and suggests one of the safeguards built into these treatments is being eroded. The researchers warn that their findings raise the risk that the effectiveness of current treatments could decline over time if resistance continues to spread.

How AI accelerates radiopharmaceutical drug discovery, optimizes personalized dosimetry

A feature News and Perspectives story on technological advances in oncology was published in Journal of Medical Internet Research. Authored by JMIR Correspondent Benedette Cuffari, "AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy" reports on the integration of deep learning and generative AI in radiopharmaceutical medicine, its impact on accelerating drug design, and how personalized dosimetry can improve patient outcomes.

Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial

Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes. The study included adults with Type 2 diabetes who were not taking diabetes medicines and whose blood sugar was not adequately controlled with diet and exercise alone.

Second prostate-specific membrane antigen PET scan can change treatment for nearly half of prostate cancer patients

A second prostate-specific membrane antigen (PSMA) PET scan changed treatment plans for nearly half of patients whose first scan was negative, according to new research published in the July issue of The Journal of Nuclear Medicine. Findings from the repeat PSMA scans, which included both local and distant disease, resulted in a change in management for nearly 50% of these patients.